Worldwide Healthcare (LON:WWH) Shares Pass Below Two Hundred Day Moving Average – What’s Next?

Worldwide Healthcare (LON:WWH) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 350.44 ($4.41) and traded as low as GBX 318 ($4.00). Worldwide Healthcare shares last traded at GBX 321.37 ($4.04), with a volume of 2,423,619 shares traded.

Worldwide Healthcare Stock Down 2.2 %

The company has a debt-to-equity ratio of 2.60, a quick ratio of 0.43 and a current ratio of 0.29. The company has a market capitalization of £1.70 billion, a PE ratio of -2,102.78 and a beta of 0.29. The firm’s 50-day simple moving average is GBX 335.61 and its 200 day simple moving average is GBX 350.44.

Worldwide Healthcare Cuts Dividend

The business also recently disclosed a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 28th will be issued a dividend of GBX 0.70 ($0.01) per share. This represents a yield of 0.21%. The ex-dividend date is Thursday, November 28th. Worldwide Healthcare’s dividend payout ratio is currently -2,000.00%.

Insiders Place Their Bets

In other Worldwide Healthcare news, insider William Hemmings acquired 7,250 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average cost of GBX 345 ($4.34) per share, for a total transaction of £25,012.50 ($31,446.44). Also, insider Sian Hansen acquired 3,017 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average cost of GBX 330 ($4.15) per share, for a total transaction of £9,956.10 ($12,517.10). 0.41% of the stock is currently owned by company insiders.

Worldwide Healthcare Company Profile

Worldwide Healthcare Trust PLC is a closed ended equity mutual fund launched by Frostrow Capital LLP. The fund is managed by OrbiMed Capital LLC. It invests in public equity markets across the globe. The fund seeks to invest in stocks of companies operating in the healthcare sector, with an emphasis on pharmaceutical and biotechnology companies.